drugset
drugset / Trial / NCT03193424

Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

NCT03193424 ↗

Phase 2 Unknown 120 enrolled The First Affiliated Hospital of Zhengzhou University
RandomizedParallel-groupSingle-blindTreatment

Summary

Esophageal cancer is a common malignant tumor in china, occupies the second place of malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.

Timeline

Start
2016-10
Primary completion
2018-12-30
Completion
2019-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2 —
Subject Rivoceranib Small molecule 500 mg Oral

Indications

esophageal squamous cell carcinoma